Stellar Biotechnologies will form a Paris-based company in a joint venture with Neovacs. The companies announced the partnership May 11. Neovacs, which is based in Paris, will own 70 percent of the new company, called Neostell. Stellar Biotechnologies will own 30 percent. Based in Port Hueneme, Stellar Biotechnologies makes a protein for immunotherapy treatments using Read More →Read More →
Loading...You are here: Home > 'Neovacs'